Ilene Weitz
Hematology · Los Angeles, CANPI 1790715399
Payments from drug & device makers
Across 780 payments — averaging $6696.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4.4M
- AstraZeneca$525K
- Bioverativ Therapeutics Inc.$86K
- Sanofi$56K
- Takeda Pharmaceuticals U.S.A., Inc.$40K
- Sanofi US Services Inc.$19K
- plus $55K from 20 others
Across 53 payments — averaging $427.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$13K
- Bioverativ Therapeutics Inc.$3K
- UCB, Inc.$2K
- Shire North American Group Inc$2K
- Novartis$1K
- Novartis Pharma AG$1K
What the payments were for
- Consulting fees$153,33024%
- Speaking & faculty fees$376,53560%
- Grants$5,6791%
- Travel & lodging$76,93112%
- Food & beverage$18,0773%
- Education$1380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 64 | $4,443,087 |
| AstraZeneca(2 entities) | 530 | $524,549 |
| Bioverativ Therapeutics Inc. | 19 | $85,908 |
| Sanofi | 39 | $55,946 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $39,981 |
| Sanofi US Services Inc. | 3 | $19,104 |
| Alnylam Pharmaceuticals Inc. | 29 | $16,765 |
| Recordati_rare_diseases_inc. | 8 | $11,480 |
| Dova Pharmaceuticals | 4 | $5,523 |
| Biocryst Pharmaceuticals, Inc. | 2 | $4,125 |
| UCB SA | 1 | $3,100 |
| Swedish Orphan Biovitrum AB | 1 | $3,000 |
| Biocryst US Sales Co., LLC | 2 | $2,841 |
| Sanofi-aventis U.S. LLC | 2 | $2,542 |
| Amgen | 11 | $2,140 |
| Incyte Corporation | 3 | $2,045 |
| Sobi, Inc | 17 | $397 |
| Apellis Pharmaceuticals, Inc. | 4 | $382 |
| Beone Medicines USA, Inc. | 4 | $87 |
| Bristol Myers Squibb | 4 | $83 |
| Johnson & Johnson | 3 | $72 |
| AbbVie | 2 | $46 |
| Blueprint Medicines Corporation | 2 | $40 |
| Agios Pharmaceuticals, Inc. | 1 | $25 |
| Grifols USA, LLC | 1 | $23 |
| Beigene USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,223,310 in reported general payments places this provider in the 90th percentile of 178 hematology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $7,975 |
Paid to pharmacies, not to this prescriber.
Other hematology in Los Angeles
- Doris QuonLos Angeles$2M
- Caroline PiatekLos Angeles$1.4M
- Tait ShanafeltStanford$441.4M
- Alex HerreraDuarte$50.9M
- Hope RugoSan Francisco$23.8M
- Tycel PhillipsDuarte$21.6M
- Lihua BuddeDuarte$21.5M
- Tanya SiddiqiDuarte$18.8M
- Amrita KrishnanDuarte$14M
- Anthony SteinDuarte$12.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.